𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder

✍ Scribed by Philip D. Harvey; Judy A. Napolitano; Lian Mao; Georges Gharabawi

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
85 KB
Volume
18
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder.

Method

One hundred seventy‐six elderly inpatients and outpatients with schizophrenia or schizoaffective disorder were enrolled in this multicenter, double‐blind trial. After their antipsychotic medications were tapered for 1 week, patients were randomly assigned to receive either risperidone 1 to 3 mg/day or olanzapine 5 to 20 mg/day for 8 weeks. Performance on the Continuous Performance Test (CPT), Serial Verbal Learning Test (SVLT), TMT (Trail Making Test) Parts A and B, Wisconsin Card Sorting Test (WCST), and Verbal Fluency Examinations (VFE) was assessed at baseline and at end point.

Results

Patients in the risperidone group had improved scores on at least one test of attention, memory, executive function, and verbal fluency, and those in the olanzapine group had improved scores on at least one test of attention and memory function. Scores on the TMT Part B, WCST total errors (executive function domain), and the VFE improved significantly from baseline in the risperidone group but not in the olanzapine group. No significant differences in change scores between the two groups were found. Higher baseline scores on each test predicted more improvement at endpoint.

Conclusions

Low doses of risperidone and olanzapine improve cognitive function in elderly patients with schizophrenia or schizoaffective disorder. Consistent with research in younger populations, these improvements occur in aspects of cognitive functioning related to functional outcome. Copyright © 2003 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Efficacy and safety of long-acting rispe
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
✍ Robert A. Lasser; Cynthia A. Bossie; Young Zhu; Georges Gharabawi; Mariëlle Eerd 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 1 views

## Abstract ## Background Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ## Objective To assess the effi

A preliminary study of the comparative e
A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia
✍ Yang-Tae Kim; Byung-Jo Kang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 2 views

## Abstract The aim of this study was to compare the effects of olanzapine and risperidone on cognitive functions in patients with schizophrenia. The subjects were schizophrenic outpatients, all meeting DSM‐IV diagnostic criteria for schizophrenia and already treated with risperidone. In the experi

Remission in schizophrenia: one-year Ita
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder
✍ Alessandro Rossi; Anna Bagalà; Vincenzo Del Curatolo; Francesco Scapati; Micaela 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

## Abstract ## Objectives To evaluate the maintenance of efficacy of risperidone long‐acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders. The prevalence of patients who met standardized remission criteria will be also evaluated as well as the predictors fac

Efficacy and tolerability of quetiapine
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone
✍ Ilkka Larmo; André de Nayer; Elmar Windhager; Irmansyah; Bernhard Lindenbauer; H 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract A __post hoc__ analysis of the SPECTRUM trial was carried out to evaluate whether the improvements in efficacy and tolerability gained on switching to quetiapine occurred consistently for patients previously treated with either: haloperidol (__n__ = 43); olanzapine (__n__ = 66); or risp

An observational study of the effectiven
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder
✍ Franca Centorrino; Adam L. Meyers; Jonna Ahl; Stephanie L. Cincotta; Leslie Zun; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## Objective To determine the effect of intramuscular (IM) olanzapine in severely agitated patients. ## Methods This was an open‐label multicenter 1‐week observational study of IM olanzapine treatment in severely agitated inpatients and psychiatric emergency services with bipolar man